This phase III trial is evaluating chemotherapy intensification in Hodgkin Lymphoma patients who receive less radiotherapy.
This trial is treating patients with Hodgkin's Disease (Hodgkin's Lymphoma).
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
Other Non-Commercial Sponsor
Royal Children's Hospital
The EuroNet-PHL-C2 trial is an international, multicentre, randomised controlled trial with the aims to reduce the indication for radiotherapy in newly diagnosed patients with classical Hodgkin lymphoma without compromising cure rates and to investigate a chemotherapy intensification randomisation in intermediate and advanced classical Hodgkin lymphoma to compensate for reduction in radiotherapy.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More